Complete blood and urine paraprotein tests as response assessments in multiple myeloma patients treated with bortezomib, cyclophosphamide, and dexamethasone.

Xialu LanFujing ZhangChen YangWei SuJianhua DuShuangjiao LiuMiao ChenBing HanDaobin ZhouJunling Zhuang

Published in: Chronic diseases and translational medicine (2023)

Urinary M protein detection rate is significantly lower than that in serum, leading to an overestimation of efficacy, premature reduction of treatment intensity, and shortened PFS. Precise response assessments are critical to treatment decisions and clinical diagnoses.

Keyphrases

multiple myeloma
low dose
high dose
small molecule
high intensity
replacement therapy
binding protein
newly diagnosed